Deprescribing antipsychotics using multiple real patient cases
Official title: Deprescribing Antipsychotics: a Multiple Case Study
Run by University Hospital, Strasbourg, France · NCT07343193 · Data updated 2026-11-12
This project will see if reducing or stopping long-term antipsychotics works for adults with stable psychotic disorders by following real-world cases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | September 9, 2025 |
| Main results expected | September 2026 |
| Study ends | September 9, 2026 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07343193 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a diagnosed psychotic or related disorder who are clinically stable on long-term antipsychotic treatment and who accept or request a planned deprescription are ideal candidates.
✕Probably not a fit
Patients who are clinically unstable, judged at high risk of relapse, or who decline to participate are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational multiple-case series at the psychiatry service of CHU de Strasbourg describing adults with psychotic or related disorders who accept or request deprescription of long-term antipsychotics. Eligible participants are clinically stable patients aged 18 or older who begin a planned reduction or discontinuation between January 1, 2021 and October 30, 2025; patients who refuse participation are excluded. The project records clinical decisions (who to deprescribe, timing, tapering rate, and relapse management) and outcomes from routine care to illustrate successes and challenges. The aim is to provide practical, real-life examples to inform clinicians and patients about deprescribing strategies and risks.
Why it matters
Potential benefit: If successful, the findings could give clinicians and patients practical examples to reduce unnecessary antipsychotic exposure and lessen treatment side effects for some people.
How similar studies have gone: Previous reports and trials have shown mixed results—some patients can taper successfully with careful plans, but relapse risk remains significant and consensus is lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) * Patients with a psychotic or related disorder * Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025 Exclusion Criteria: \- Patients who have expressed their opposition to participating in the study
Where it's running
-
Service de Psychiatrie 1 - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Fabrice BERNA, MD, PhD
- Email: fabrice.berna@chru-strasbourg.fr
- Phone: 33 3 88 11 64 62
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Speech-based test to estimate relapse risk in psychosis
This project will try using weekly smartphone speech recordings and short self-reports to see if an automated system can predict relapse risk in people with psychosis.
-
Changing Lives and Changing Outcomes-9 group program at Worcester Recovery Center and Hospital
This program will try a nine-session cognitive-behavioral group to help adults with serious mental illness who have current or past legal involvement increase mental health awareness and lower chances of future legal problems.
-
Cognitive Strategies in Early Psychosis 2 – how brain games and pills test decision making
This study tests whether a single dose of modafinil or d-serine, compared with placebo, changes decision making in people aged 18–35 who have recently begun experiencing psychosis.
-
Long-term supervised exercise program to improve fitness and quality of life for inpatients with psychosis
This program tries a long-term supervised exercise routine, including Pilates, to see if it improves physical function and quality of life for adults hospitalized with psychotic disorders.
-
iTEST: a blended mobile program to improve introspective accuracy (accurate self-judgment of abilities)
This trial tests whether iTEST — daily mobile cognitive training plus coaching that focuses on accurate self-judgment — helps adults with schizophrenia-spectrum or other psychotic disorders improve community functioning.
-
Connectivity-guided theta-burst stimulation targeting the hippocampus in schizophrenia
We will try targeted theta-burst TMS guided by brain connectivity to change hippocampus activity in adults with schizophrenia or related psychotic disorders, measuring brain signals with EEG and, for some participants, intracranial electrodes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.